Startups

NMD Pharma
Aarhus, Denmark · Boston, Massachusetts, United States
NMD Pharma A/S is a Danish clinical-stage biotechnology company (CVR36899069), incorporated as an Aarhus University spin-out in2015, headquartered in Aarhus with US operations. It develops small-molecule therapies targeting skeletal-muscle chloride channel ClC-1 to improve neuromuscular transmission and muscle function. Its investigational lead ignaseclant, formerly NMD670, is being evaluated in Charcot-Marie-Tooth disease, generalized myasthenia gravis and spinal muscular atrophy. Additional research addresses age-related muscle weakness and sarcopenia. Its neuroscience relevance is neuromuscular biology and drug development; no unsupported claim that its platform is artificial intelligence is made. The current primary website publishes seven management members, fifty-nine other team members, eight board members including the CEO, and three founding scientists. Functions not published in the general team directory remain qualified as Team Member; founding-scientist status is distinct from current executive employment. Current CMO Ana de Vera joined September2025, superseding older Jorge Quiroz CMO announcements. Current board affiliations are separately sourced and do not establish personal cash investments. Actual primary funding includes a EUR2.7million seed investment in2016, a EUR38million SeriesA announced March23,2018, EUR35million financing announced February15,2022 (stage undisclosed in the issuer release), and EUR75million SeriesB announced November15,2023. A separate EUR629000 Innovation Fund Denmark grant was reported received November30,2020. The2014 EUR330000 pre-seed grant funded Aarhus University before incorporation and is not company financing. Historical2016–17 DKK44million cumulative support and later cumulative EUR155million or approximately USD180million statements are not separate new rounds. Closed company cash, grant awards, historical totals and currency renditions remain distinct.










































































